Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma

被引:29
作者
Cheung, Tan-To [1 ]
Kwok, Philip Chong-Hei [2 ]
Chan, Stephen [3 ]
Cheung, Chin-Cheung [4 ]
Lee, Ann-Shing [5 ]
Lee, Victor [6 ]
Cheng, Hoi-Ching [7 ]
Nam-Hung Chia [8 ]
Chong, Charing C. N. [9 ]
Lai, Tak-Wing [10 ]
Law, Ada L. Y. [11 ]
Luk, Mai-Yee [6 ]
Tong, Chi Chung [6 ]
Yau, Thomas C. C. [12 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[2] Queen Elizabeth Hosp, Dept Radiol & Imaging, Hong Kong, Hong Kong, Peoples R China
[3] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[4] Tuen Mun Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[5] Tuen Mun Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[6] Univ Hong Kong, Queen Mary Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[7] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[8] Queen Elizabeth Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[9] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[10] Princess Margaret Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[11] Pamela Youde Nethersole Eastern Hosp, Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[12] Univ Hong Kong, Queen Mary Hosp, Dept Med & Surg, Hong Kong, Hong Kong, Peoples R China
关键词
Consensus; Hepatocellular carcinoma; Unresectable HCC; Hong Kong; RANDOMIZED CONTROLLED-TRIAL; SELECTIVE INTERNAL RADIATION; PORTAL-VEIN EMBOLIZATION; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; STEREOTACTIC BODY RADIOTHERAPY; MICROWAVE COAGULATION THERAPY; FOCUSED ULTRASOUND ABLATION; CANCER STAGING SYSTEM; RADIOFREQUENCY ABLATION; PHASE-III;
D O I
10.1159/000485984
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Hepatocellular carcinoma (HCC) is highly prevalent in Hong Kong due to the high prevalence of chronic hepatitis B infection. Liver cancer is the fourth most common cancer and the third most common cause of cancer death. Due to the high case load, there is a high level of local expertise in treating HCC, and the full spectrum of treatment modalities is available. This document summarizes how these modalities should be used based on the latest evidence. Summary: In 2 meetings held in early 2017, a multidisciplinary group of Hong Kong clinicians, including liver surgeons, interventional radiologists, clinical oncologists, and medical oncologists, met to update local consensus statements for management of HCC. These statements are based on the latest evidence and give detailed guidance on how to deploy these modalities, in particular for cases of HCC which are not suited to surgical resection. Key Messages: These statements give detailed information on how to decide if a patient is a candidate for resection, methods to improve candidacy for resection, and guidance for use of various nonsurgical interventions to manage patients ineligible for resection. (c) 2018 S. Karger AG, Basel
引用
收藏
页码:40 / 54
页数:15
相关论文
共 95 条
  • [22] Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma
    Culleton, Shaelyn
    Jiang, Haiyan
    Haddad, Carol R.
    Kim, John
    Brierley, Jim
    Brade, Anthony
    Ringash, Jolie
    Dawson, Laura A.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2014, 111 (03) : 412 - 417
  • [23] Percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma: Results in 234 patients
    Dong, BW
    Liang, P
    Yu, XL
    Su, L
    Yu, DJ
    Cheng, ZG
    Zhang, J
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2003, 180 (06) : 1547 - 1555
  • [24] Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis
    Duan, Chenyang
    Liu, Mengying
    Zhang, Zhuohang
    Ma, Kuansheng
    Bie, Ping
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2013, 11
  • [25] Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
    El-Khoueiry, Anthony B.
    Sangro, Bruno
    Yau, Thomas
    Crocenzi, Todd S.
    Kudo, Masatoshi
    Hsu, Chiun
    Kim, Tae-You
    Choo, Su-Pin
    Trojan, Jorg
    Welling, Theodore H., III
    Meyer, Tim
    Kang, Yoon-Koo
    Yeo, Winnie
    Chopra, Akhil
    Anderson, Jeffrey
    dela Cruz, Christine
    Lang, Lixin
    Neely, Jaclyn
    Tang, Hao
    Dastani, Homa B.
    Melero, Ignacio
    [J]. LANCET, 2017, 389 (10088) : 2492 - 2502
  • [26] Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization:: Comparison of planned periodic chemoembolization and chemoembolization based on tumor response
    Ernst, O
    Sergent, G
    Mizrahi, D
    Delemazure, O
    Paris, JC
    L'Herminé, C
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 1999, 172 (01) : 59 - 64
  • [27] Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis
    Facciorusso, Antonio
    Serviddio, Gaetano
    Muscatiello, Nicola
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2016, 8 (18) : 770 - 778
  • [28] Continuous Improvement of Survival Outcomes of Resection of Hepatocellular Carcinoma A 20-Year Experience
    Fan, Sheung Tat
    Lo, Chung Mau
    Poon, Ronnie T. P.
    Yeung, Chun
    Liu, Chi Leung
    Yuen, Wai Key
    Lam, Chi Ming
    Ng, Kelvin K. C.
    Chan, See Ching
    [J]. ANNALS OF SURGERY, 2011, 253 (04) : 745 - 758
  • [29] Liver functional reserve estimation: state of the art and relevance for local treatments - The Eastern perspective
    Fan, Sheung Tat
    [J]. JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2010, 17 (04) : 380 - 384
  • [30] Food & Drug Administration, FDA GRANTS ACC APPR